Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies

NCT01163201 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT01163201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01163201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 31, 2014
Completion date
January 31, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myeloid leukemia, anemia, refractory, with excess of blasts, burkitt's lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia in blast crisis, chronic myeloproliferative disease, follicular lymphoma, hematologic malignancy, high grade non-hodgkin's lymphoma, large cell non-hodgkin's lymphoma, lymphoblastic lymphoma, lymphoplasmacytic lymphoma, mantle-cell lymphoma, marginal zone b-cell lymphoma, prolymphocytic lymphoma, small lymphocytic lymphoma